Oncology Trials Are Taking Longer
KMR Group has recently assessed the duration of oncology trials.
KMR Group, a leader in analyzing R&D performance data for the biopharmaceutical industry, has recently assessed the duration of oncology trials. There has been a steady rise in late stage oncology cycle times in the last 10 years.
KMR Group assessed cycle time trends for more than 4100 oncology trials using proprietary industry data across 32 companies.
Over the last decade oncology cycle times have risen steadily in Phases II and III. Phase II oncology trials require about one additional year, compared to trials conducted a decade ago. Phase III trials are taking almost five years, which is one and a half years longer than trials in 2003-2005.
KMR defines study duration as the interval from Protocol Approval to Database Lock.
These trends raise an important question: What is causing such significant increases in oncology trial cycle times, particularly in Phases II and III where there has been a significant shift?
There are oncology specific considerations in the increase in trial durations such as increasing protocol complexity and trial design, longer treatment periods, more factors tested in trials, e.g., biomarkers, multiple diseases, multiple endpoints, and an increasing number of subjects involved. However, these are not the only explanations.
The varied ways companies approach operational aspects of running clinical trials can have substantial effect on key clinical trial processes. KMR Group performs extensive analysis on critical trial processes that affect overall cycle times.
“In assessing operation aspects, the enrollment and treatment processes have expanded by almost six months each (treatment duration nearly doubled since 2003-2005). We have also seen the impact of process-oriented or operational areas where companies can find clear opportunities for improvement. These include study startup, site initiation and site selection, as well as the performance of individual sites. The focus of these efforts is to optimize the enrollment process, with a goal of reducing cycle times and faster time to market,” commented Linda Martin of KMR Group.
For more information please contact: Linda Martin, President & Founder
Tel: +1 (312) 795-0400 Email: lmartin [at] kmrgroup.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
